Clinical trials: Carcinoma of Prostate (Disorder)
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Prostate Cancer
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker…
- Trial name
- NCT03871816
- Testing
- Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
- Where
- 338 sites in United States, Argentina and 23 more
- Volunteers
- 14,532 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of…
- Trial name
- NCT01188408
- Testing
- Liposome Entrapped Docetaxel (LE-DT)
- Where
- 2 sites in United States
- Sponsor
- INSYS Therapeutics Inc
Advanced Solid Tumors
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
- Trial name
- WEE1 (NCT04768868)
- Testing
- IMP7068
- Where
- 16 sites in United States, China and 1 more
- Volunteers
- 350 people
- Sponsor
- Impact Therapeutics, Inc.
Prostate Cancer, Leukemia
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Study Description: ELEA is an observational cohort study that will collect exposure information and biospecimens from the adult children of the Agricultural Health Study (AHS) cohort (https://aghealth.nih.gov/about; Protocol…
- Conditions
- Prostate Cancer, Leukemia, Breast Cancer, Melanoma
- Trial name
- NCT07328516
- Where
- United States
- Volunteers
- 64,277 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs…
- Trial name
- ERA 223 (NCT02043678)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone, Prednisone/Prednisolone
- Where
- 163 sites in United States, Australia and 17 more
- Volunteers
- 806 people
- Sponsor
- Bayer
Prostate Cancer, Radiotherapy Side Effect
Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.
The majority of all new prostate cancer cases are diagnosed in men aged > 70 years, with the highest incidence in men aged > 90 years.
- Trial name
- NCT04535908
- Testing
- Hypofractionated radiotherapy
- Where
- Austria
- Volunteers
- 23 people
- Sponsor
- Medical University of Graz
Metastatic Prostate Cancer
Physician- and Patient-based Barriers to NGS Testing
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer.
- Trial name
- NCT07209176
- Testing
- Provider-level and patient education at end of study, Provider-level and patient-level
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX.
- Trial name
- NCT00846976
- Testing
- Bicalutamide
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Hot Flashes, Prostate Cancer
Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
RATIONALE: Gabapentin may be effective in relieving hot flashes in men who have prostate cancer. It is not yet known which regimen of gabapentin is most effective in treating hot flashes.
- Trial name
- NCT00028574
- Testing
- gabapentin
- Where
- 170 sites in United States
- Volunteers
- 223 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
The present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin A.
- Trial name
- NCT00166725
- Testing
- Octreotide LAR
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Novartis
Prostate Cancer
Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies
Prostate cancer has been the most common neoplastic disease in men in Finland over the last ten years. Prostate-specific antigen (PSA) plays an important role in screening of prostate cancer.
- Trial name
- PROMANEG (NCT02388126)
- Testing
- 3T multiparametric MRI, Transrectal ultrasound
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Turku University Hospital
Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically…
- Conditions
- Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
- Trial name
- RADVAN (NCT07477626)
- Testing
- Androgen Deprivation Therapy (ADT), radiotherapy
- Where
- 13 sites in China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Effect of Optimized PEEP on Mechanical Ventilation During Robot Assisted Laparoscopic Prostatectomy
Steep trendelenburg posture or pneumoperitoneum for surgery causes ventilation problems during surgery, so finding a way to overcome is a challenging task for anesthesiologists.
- Trial name
- NCT05669443
- Testing
- conventional PEEP, optimized PEEP
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Gangnam Severance Hospital
Prostate Cancer
Recommended Dose Estimation of BP-C2
The aim is to estimate an oral administered recommended dose of BP-C2 in addition to hormone treatment of prostate cancer. The study population consists of prostatic cancer patients between 18 and 80 years of age undergoing…
- Trial name
- NCT04186585
- Testing
- BP-C2
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Meddoc
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu
Prostate Cancer
Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
There are two parts to this study: (1) an information gathering phase leading to development of a new decision aid (phase 1); and (2) a study to test the newly developed decision aid (phase 2).
- Trial name
- NCT00815750
- Testing
- Information Gathering, Decision Aid
- Where
- 2 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
This is a multi-center, single-arm, open-label, phase III trial in patients with biopsy-proven prostate cancer. Patients will receive regular standard of clinical care.
- Trial name
- NCT03459820
- Testing
- 18F-DCFPyL PET/CT
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments.
- Trial name
- NCT07203482
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- NYU Langone Health
Prostate Carcinoma
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer.
- Trial name
- MSG PSMA PET (NCT04282824)
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.